Biomarkers in Acute Heart Failure: An International, Multi-Center Trial Evaluating the Prognostic and Diagnostic Utility of Biomarkers in Patients With Heart Failure Presenting With Shortness of Breath
1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart
failure (HF) patients and adds incremental value in predicting outcomes for patients
presenting to the Emergency Department (ED) with shortness of breath.
2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the
diagnosis of HF in patients presenting to the ED with shortness of breath.
Study Status: Completed
Shortness of Breath
Information provided by:
Study Type: Interventional
Study Design: Cohort, Prospective
The Cleveland Clinic
Cleveland, Ohio 44195
Alan S Maisel, MD., Principal Investigator
Stefan D Anker, MD, PhD., Principal Investigator
Frank Peacock, MD., Study Chair